immune system
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
|
• massive expansion in tamoxifen-treated mice
|
• massive expansion in tamoxifen-treated mice
|
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
|
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro
|
hematopoietic system
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
|
• massive expansion in tamoxifen-treated mice
|
• massive expansion in tamoxifen-treated mice
|
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
|
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro
|
growth/size/body
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|